Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Assets (2022 - 2026)

Kura Oncology has reported Assets over the past 5 years, most recently at $652.6 million for Q1 2026.

  • Quarterly Assets fell 12.26% to $652.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $652.6 million through Mar 2026, down 12.26% year-over-year, with the annual reading at $738.4 million for FY2025, 2.87% down from the prior year.
  • Assets was $652.6 million for Q1 2026 at Kura Oncology, down from $738.4 million in the prior quarter.
  • Over five years, Assets peaked at $760.2 million in Q4 2024 and troughed at $426.0 million in Q1 2023.
  • The 5-year median for Assets is $534.5 million (2024), against an average of $576.7 million.
  • Year-over-year, Assets soared 69.32% in 2024 and then dropped 12.26% in 2026.
  • A 5-year view of Assets shows it stood at $456.3 million in 2022, then dropped by 1.62% to $448.9 million in 2023, then surged by 69.32% to $760.2 million in 2024, then decreased by 2.87% to $738.4 million in 2025, then dropped by 11.62% to $652.6 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Assets are $652.6 million (Q1 2026), $738.4 million (Q4 2025), and $649.4 million (Q3 2025).